Literature DB >> 26008738

Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency.

Yusuke Higuchi, Cu Nguyen, Shin-Ya Yasuda, Michael McMillan, Kouichi Hasegawa, Michael Kahn1.   

Abstract

Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26008738     DOI: 10.2174/1874467208666150526155146

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  12 in total

Review 1.  Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.

Authors:  Shilong Zheng; Jiawang Liu; Yanyuan Wu; Tien L Huang; Guangdi Wang
Journal:  Future Med Chem       Date:  2015-12-16       Impact factor: 3.808

2.  Wnt/β-catenin regulates blood pressure and kidney injury in rats.

Authors:  Liangxiang Xiao; Bo Xu; Lili Zhou; Roderick J Tan; Dong Zhou; Haiyan Fu; Aiqing Li; Fan Fan Hou; Youhua Liu
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-01-30       Impact factor: 5.187

Review 3.  CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

Authors:  Yong-Mi Kim; Eun-Ji Gang; Michael Kahn
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

Review 4.  Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.

Authors:  Michael Kahn
Journal:  Expert Opin Ther Targets       Date:  2021-10-27       Impact factor: 6.902

5.  p300 Serine 89: A Critical Signaling Integrator and Its Effects on Intestinal Homeostasis and Repair.

Authors:  Keane K Y Lai; Xiaohui Hu; Keisuke Chosa; Cu Nguyen; David P Lin; Keith K Lai; Nobuo Kato; Yusuke Higuchi; Sarah K Highlander; Elizabeth Melendez; Yoshihiro Eriguchi; Patrick T Fueger; Andre J Ouellette; Nyam-Osor Chimge; Masaya Ono; Michael Kahn
Journal:  Cancers (Basel)       Date:  2021-03-14       Impact factor: 6.639

6.  Small molecule p300/catenin antagonist enhances hematopoietic recovery after radiation.

Authors:  Yi Zhao; Kaijin Wu; Cu Nguyen; Goar Smbatyan; Elisabeth Melendez; Yusuke Higuchi; Yibu Chen; Michael Kahn
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

7.  ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.

Authors:  Darina Lazarova; Michael Bordonaro
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

8.  Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance.

Authors:  Andrea Bild; Jia-Ling Teo; Michael Kahn
Journal:  Cancer Drug Resist       Date:  2019-09-19

9.  Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage.

Authors:  Masaya Ono; Keane K Y Lai; Kaijin Wu; Cu Nguyen; David P Lin; Ramachandran Murali; Michael Kahn
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

10.  Convergence of Canonical and Non-Canonical Wnt Signal: Differential Kat3 Coactivator Usage.

Authors:  Keane K Y Lai; Cu Nguyen; Kyung-Soon Lee; Albert Lee; David P Lin; Jia-Ling Teo; Michael Kahn
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.